Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 Jul;100(3):600–604. doi: 10.1111/j.1476-5381.1990.tb15853.x

Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit.

J Feldman 1, E Tibiriça 1, G Bricca 1, M Dontenwill 1, A Belcourt 1, P Bousquet 1
PMCID: PMC1917804  PMID: 2390682

Abstract

1. Rilmenidine has recently been introduced as a new centrally-acting antihypertensive agent. We examined its cardiovascular effects after intracerebral injection to anaesthetized rabbits. Cumulative doses of rilmenidine injected intracisternally (1 to 300 micrograms kg-1) led to dose-dependent decreases in arterial blood pressure and heart rate. The effective doses of rilmenidine were lower when injected centrally than when injected intravenously. 2. Pretreatment with the same dose of yohimbine or idazoxan shifted the rilmenidine dose-response curves for its hypotensive and bradycardic effects to the right. Idazoxan, which has an imidazoline structure, proved to be a more active antagonist than yohimbine of rilmenidine centrally-mediated cardiovascular effects. 3. The dose-response curve for the central hypotensive effect of rilmenidine was also shifted to the right after pretreatment with a bovine brain extract. This extract contains the endogenous ligand of the imidazoline-preferring receptors which is not a catecholamine. 4. Rilmenidine, like clonidine, proved to be active when micro-injected into the rabbit nucleus reticularis lateralis region. 5. In conclusion, rilmenidine exhibited in the rabbit a central hypotensive effect which originated in the same area as where clonidine acts. Specific imidazoline-preferring receptors appear to be involved in this hypotensive effect.

Full text

PDF
600

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atlas D., Burstein Y. Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur J Biochem. 1984 Oct 15;144(2):287–293. doi: 10.1111/j.1432-1033.1984.tb08462.x. [DOI] [PubMed] [Google Scholar]
  2. Atlas D., Burstein Y. Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS Lett. 1984 May 21;170(2):387–390. doi: 10.1016/0014-5793(84)81350-2. [DOI] [PubMed] [Google Scholar]
  3. Atlas D., Diamant S., Fales H. M., Pannell L. The brain's own clonidine: purification and characterization of endogenous clonidine displacing substance from brain. J Cardiovasc Pharmacol. 1987;10 (Suppl 12):S122–S127. [PubMed] [Google Scholar]
  4. Bousquet P., Feldman J., Atlas D. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur J Pharmacol. 1986 May 13;124(1-2):167–170. doi: 10.1016/0014-2999(86)90138-x. [DOI] [PubMed] [Google Scholar]
  5. Bousquet P., Feldman J., Bloch R., Schwartz J. The nucleus reticularis lateralis: a region highly sensitive to clonidine. Eur J Pharmacol. 1981 Jan 29;69(3):389–392. doi: 10.1016/0014-2999(81)90490-8. [DOI] [PubMed] [Google Scholar]
  6. Bousquet P., Feldman J., Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther. 1984 Jul;230(1):232–236. [PubMed] [Google Scholar]
  7. Bousquet P., Feldman J., Tibirica E., Bricca G., Molines A., Dontenwill M., Belcourt A. New concepts on the central regulation of blood pressure. Alpha 2-adrenoceptors and "imidazoline receptors". Am J Med. 1989 Sep 18;87(3C):10S–13S. doi: 10.1016/0002-9343(89)90498-1. [DOI] [PubMed] [Google Scholar]
  8. Bousquet P., Guertzenstein P. G. Localization of the central cardiovascular action of clonidine. Br J Pharmacol. 1973 Dec;49(4):573–579. doi: 10.1111/j.1476-5381.1973.tb08532.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bricca G., Dontenwill M., Molines A., Feldman J., Belcourt A., Bousquet P. Evidence for the existence of a homogeneous population of imidazoline receptors in the human brainstem. Eur J Pharmacol. 1988 Jun 10;150(3):401–402. doi: 10.1016/0014-2999(88)90028-3. [DOI] [PubMed] [Google Scholar]
  10. Bricca G., Dontenwill M., Molines A., Feldman J., Belcourt A., Bousquet P. The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur J Pharmacol. 1989 Mar 14;162(1):1–9. doi: 10.1016/0014-2999(89)90597-9. [DOI] [PubMed] [Google Scholar]
  11. Bricca G., Dontenwill M., Molines A., Feldman J., Tibirica E., Belcourt A., Bousquet P. Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol. 1989 Apr 25;163(2-3):373–377. doi: 10.1016/0014-2999(89)90210-0. [DOI] [PubMed] [Google Scholar]
  12. Doxey J. C., Roach A. G., Smith C. F. Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors. Br J Pharmacol. 1983 Mar;78(3):489–505. doi: 10.1111/j.1476-5381.1983.tb08809.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Doxey J. C., Roach A. G., Strachan D. A., Virdee N. K. Selectivity and potency of 2-alkyl analogues of the alpha 2-adrenoceptor antagonist idazoxan (RX 781094) in peripheral systems. Br J Pharmacol. 1984 Nov;83(3):713–722. doi: 10.1111/j.1476-5381.1984.tb16225.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ernsberger P., Meeley M. P., Mann J. J., Reis D. J. Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol. 1987 Jan 28;134(1):1–13. doi: 10.1016/0014-2999(87)90125-7. [DOI] [PubMed] [Google Scholar]
  15. Ernsberger P., Meeley M. P., Reis D. J. An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medulla. Brain Res. 1988 Feb 16;441(1-2):309–318. doi: 10.1016/0006-8993(88)91409-6. [DOI] [PubMed] [Google Scholar]
  16. Granata A. R., Reis D. J. Hypotension and bradycardia elicited by histamine into the C1 area of the rostral ventrolateral medulla. Eur J Pharmacol. 1987 Apr 14;136(2):157–162. doi: 10.1016/0014-2999(87)90707-2. [DOI] [PubMed] [Google Scholar]
  17. Hamilton C. A., Reid J. L., Yakubu M. A. [3H]yohimbine and [3H]idazoxan bind to different sites on rabbit forebrain and kidney membranes. Eur J Pharmacol. 1988 Feb 9;146(2-3):345–348. doi: 10.1016/0014-2999(88)90314-7. [DOI] [PubMed] [Google Scholar]
  18. Head G. A., de Jong W. Differential blood pressure responses to intracisternal clonidine, alpha-methyldopa, and 6-hydroxydopamine in conscious normotensive and spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):735–742. [PubMed] [Google Scholar]
  19. Laubie M., Poignant J. C., Scuvée-Moreau J., Dabire H., Dresse A., Schmitt H. Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S 3341), an alpha-2 adrenoceptor agonist. J Pharmacol. 1985 Jul-Sep;16(3):259–278. [PubMed] [Google Scholar]
  20. McAuley M. A., Macrae I. M., Reid J. L. The cardiovascular actions of clonidine and neuropeptide-Y in the ventrolateral medulla of the rat. Br J Pharmacol. 1989 Aug;97(4):1067–1074. doi: 10.1111/j.1476-5381.1989.tb12563.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Meeley M. P., Ernsberger P. R., Granata A. R., Reis D. J. An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci. 1986 Mar 24;38(12):1119–1126. doi: 10.1016/0024-3205(86)90248-1. [DOI] [PubMed] [Google Scholar]
  22. Tibirica E., Feldman J., Bousquet P. Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats. J Pharmacol Exp Ther. 1988 Mar;244(3):1062–1066. [PubMed] [Google Scholar]
  23. Wolf D. L., Mohrland J. S. Lateral reticular formation as a site for morphine- and clonidine-induced hypotension. Eur J Pharmacol. 1984 Feb 10;98(1):93–98. doi: 10.1016/0014-2999(84)90112-2. [DOI] [PubMed] [Google Scholar]
  24. van Zwieten P. A., Thoolen M. J., Jonkman F. A., Wilffert B., de Jonge A., Timmermans P. B. Central and peripheral effects of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models. Arch Int Pharmacodyn Ther. 1986 Jan;279(1):130–149. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES